Hormone therapy and breast cancer risk 10 years after the WHI

References

• WHI Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, . Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• Karim R, Dell R, Greene D, Mack W, Gallagher J, Hodis H. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011;18:1172–7
   PubMed Web of Science ®Google Scholar
• Arnal J, Lenfant F, Flouriot G, . From in vivo gene targeting of oestrogen receptors to optimization of their modulation in menopause. Br J Pharmacol 2012;165:57–66
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Santen RJ. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Women's Health 2008;4:207–10
   Google Scholar
• Santen RJ, Allred DC, Ardoin SP, . Postmenopausal hormone therapy: an Endocrine Society Scientific Statement. J Clin Endocrinol Metab 2010;95(Suppl 1):s1–66
   Web of Science ®Google Scholar
• Foidart J-M, Desreux J, Pintiaux A, Gompel A. Hormone therapy and breast cancer risk. Climacteric 2007;10(Suppl 2):54–61
   PubMedGoogle Scholar
• Chen WY, Manson JE, Hankinson SE, . Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–32
   PubMed Web of Science ®Google Scholar
• Bakken K, Fournier AS, Lund E, . Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011;128:144–56
   PubMed Web of Science ®Google Scholar
• Song R, Mor G, Naftolin F, . Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93:1714–23
   PubMedGoogle Scholar
• Ariazi E, Cunliffe HE, Lewis-Wambi J, . Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci 2011;108:18879–86
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol–progestogen therapy. Obstet Gynecol 2009;113:65–73
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–74
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Thun M. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28
   PubMed Web of Science ®Google Scholar
• Li CI, Daling JR. Changes in breast cancer incidence rates in the United States by histologic subtype and race/ethnicity, 1995 to 2004. Cancer Epidemiol Biomarkers Prev 2007;16:2773–80
   PubMed Web of Science ®Google Scholar
• Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152–61
   PubMed Web of Science ®Google Scholar
• Caan B, Habel L, Quesenberry C, Kushi L, Herrinton L. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 2008;100:597–98
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Cook AJ, Buist DSM, . Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010;28:3830–7
   PubMed Web of Science ®Google Scholar
• Gompel A, Plu-Bureau G. Is the decrease in breast cancer incidence related to a decrease in postmenopausal hormone therapy? Ann NY Acad Sci 2010;1205:268–76
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism. Arterioscl Thromb Vasc Biol 2010;30:340–5
   PubMed Web of Science ®Google Scholar
• Renous C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Fournier A, Kernaleguen C, Panjo H, Clavel-Chapelon F, Ringa V. Postmenopausal hormone therapy initiation before and after the Women's Health Initiative in two French cohorts. Menopause 2011;18:219–23
   PubMed Web of Science ®Google Scholar
• Zahl P-H, Maehlen J. A decline in breast-cancer incidence. N Engl J Med 2007;357:510–11
   PubMed Web of Science ®Google Scholar
• Antoine C, Ameye L, Moreau M, Paesmans M, Rozenberg S. Evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium. Climacteric 2011;14: 464–71
   PubMed Web of Science ®Google Scholar
• Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet 2008;372:608–10
   PubMed Web of Science ®Google Scholar
• Kliewer E, Demers A, Nugent Z. A decline in breast-cancer incidence. N Engl J Med 2007;357:509–10
   PubMedGoogle Scholar
• Neutel CI, Morrison H. Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. Can J Public Health 2010;101:405–9
   PubMed Web of Science ®Google Scholar
• Hery C, Ferlay J, Boniol M, Autier P. Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with Caucasian-majority populations. Ann Oncol 2008;19: 1187–94
   PubMed Web of Science ®Google Scholar
• Suhrke P, Maehlen Jan, Schlichting E, Jorgensen K, Gotzsche P, Zahl P. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ 2011;343:d4692
   PubMed Web of Science ®Google Scholar
• Li CI, Chlebowski RT, Freiberg M, . Alcohol consumption and risk of postmenopausal breast cancer by subtype:the Women's Health Initiative observational study. J Natl Cancer Inst 2010;102:1422–31
   PubMed Web of Science ®Google Scholar
• Chen WY, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 2011;306:1884–90
   PubMed Web of Science ®Google Scholar
• Farhat GN, Walker R, Buist DSM, Onega T, Kerlikowske K. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 2010;28:5140–6
   PubMed Web of Science ®Google Scholar
• DeSantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 2011;20:733–9
   PubMed Web of Science ®Google Scholar
• Canada Public Health Agency 2009, Cancer Surveillance On-Line http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cancer/index_e.html
   Google Scholar
• Rennstam K, Ringberg A, Cunliffe HE, Olsson H, Landberg G, Hedenfalk I. Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosom Cancer 2010;49: 78–90
   PubMed Web of Science ®Google Scholar
• Boyd N, Martin L, Yaffe M, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011;13:223
   PubMed Web of Science ®Google Scholar
• Cuzick J, Warwick J, Pinney E, . Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011;103:744–52
   PubMed Web of Science ®Google Scholar
• Crandall C, Aragaki A, Cauley J, . Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone Women's Health Initiative clinical trials. Breast Cancer Res Treat 2012;132:275–85
   PubMed Web of Science ®Google Scholar
• Plu-Bureau G, Thalabard JC, Sitruk-Ware R, Asselain B, Mauvais-Jarvis P. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women. Br J Cancer 1992;65:945–9
   PubMed Web of Science ®Google Scholar
• Goodwin P, DeBoer G, Clark R, . Cyclical mastopathy and premenopausal breast cancer risk. Results of a case-control study. Breast Cancer Res Treat 1995;33:63–73
   PubMed Web of Science ®Google Scholar
• McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. Am J Roentgenol 1994;163:311–15
   PubMed Web of Science ®Google Scholar
• Kwan ML, Kushi LH, Weltzien E, . Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: the Life After Cancer Epidemiology Study. J Clin Oncol 2010;28:4410–16
   PubMed Web of Science ®Google Scholar
• Pichard C, Plu-Bureau G, Neves-e-Castro M, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 2008;60: 19–30
   PubMed Web of Science ®Google Scholar
• Friedenreich CM. The role of physical activity in breast cancer etiology. Semin Oncol 2010;37:297–302
   PubMed Web of Science ®Google Scholar
• Tehard B, Friedenreich CM, Oppert J-M, Clavel-Chapelon F. Effect of physical activity on women at increased risk of breast cancer: results from the E3N cohort study. Cancer Epidemiol Biomarkers Prev 2006;15:57–64
   PubMed Web of Science ®Google Scholar
• Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 2008;42:636–47
   PubMed Web of Science ®Google Scholar
• Petracci E, Decarli A, Schairer C, . Risk factor modification and projections of absolute breast cancer risk. J Natl Cancer Inst 2011;103:1037–48
   PubMed Web of Science ®Google Scholar
• Santen RJ. Endocrine-responsive cancer. In Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology, 11th edn. Philadelphia: Saunders Elsevier, 2008: 1764
   Google Scholar